Yahoo Finance

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

BOSTON, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ...
MarketWatch

Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.
Yahoo Finance

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta ...

BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, ...
Benzinga.com

Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms

This open-label study included 19 patients from clinical sites in Ireland and the United States. The majority of patients were female (68.4%) and the average age was 42 years. The primary endpoint was ...
Business Wire

COMPaSS™ Personalized Spine Surgery Study Begins Enrollment

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed ® announced today that the first patients have been enrolled in the COMPaSS™ study. COMPaSS, Clinical Outcome Measures in Personalized aprevo ® Spine ...